Michigan SB0094 prohibits drug manufacturers from limiting access to 340B drugs and requires reporting on drug costs and audits.
Michigan SB0094 amends the Public Health Code to prohibit drug manufacturers, wholesalers, and wholesale distributors from limiting access to 340B drugs for entities participating in the federal 340B drug pricing program. The bill also mandates that 340B entities submit annual reports to the Department of Health and Human Services and legislative fiscal agencies, detailing drug costs, market introduction dates, and compliance with 340B program audits. Additionally, manufacturers must report on drugs with significant cost increases. The bill's provisions take effect only if Senate Bill No.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.